These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2283251)

  • 1. Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection.
    Van Wagoner M; O'Toole M; Quay SC
    Invest Radiol; 1990 Sep; 25 Suppl 1():S39-41. PubMed ID: 2283251
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can gadolinium be safely given in renal failure?
    Weissleder R
    AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
    Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
    [No Abstract]   [Full Text] [Related]  

  • 5. Contrast agents in magnetic resonance imaging.
    Roux E; De Broe L
    J Belge Radiol; 1988; 71(1):31-6. PubMed ID: 3372466
    [No Abstract]   [Full Text] [Related]  

  • 6. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure.
    Haustein J; Niendorf HP; Krestin G; Louton T; Schuhmann-Giampieri G; Clauss W; Junge W
    Invest Radiol; 1992 Feb; 27(2):153-6. PubMed ID: 1601607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine.
    Sze G; Brant-Zawadzki M; Haughton VM; Maravilla KR; McNamara MT; Kumar AJ; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Radiology; 1991 Dec; 181(3):693-9. PubMed ID: 1947084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR contrast enhancement of intracranial lesions with Gd-DTPA.
    Hesselink JR; Press GA
    Radiol Clin North Am; 1988 Jul; 26(4):873-87. PubMed ID: 3289078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective.
    Aslanian V; Lemaignen H; Bunouf P; Svaland MG; Borseth A; Lundby B
    Neuroradiology; 1996 Aug; 38(6):537-41. PubMed ID: 8880714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.
    Akeson P; Jonsson E; Haugen I; Holtås S
    Neuroradiology; 1995 Apr; 37(3):229-33. PubMed ID: 7603600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with gadodiamide injection in magnetic resonance imaging of the central nervous system.
    Andrew E; Svaland M; Lundby B; Hugo F; LaFrance N
    Invest Radiol; 1994 Jun; 29 Suppl 2():S186-8. PubMed ID: 7928225
    [No Abstract]   [Full Text] [Related]  

  • 12. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
    Van Wagoner M; Worah D
    Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
    Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
    Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system.
    Valk J; Algra PR; Hazenberg CJ; Slooff WB; Svaland MG
    Neuroradiology; 1993; 35(3):173-7. PubMed ID: 8459913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system.
    Ekholm S; Jonsson E; Sandvik L; Fagerlund M; Holtås S; Isberg B; Lindell D; Lindén B; Sjöberg S; Thuomas KA; Tollesson PO
    Acta Radiol; 1996 Mar; 37(2):223-8. PubMed ID: 8600967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous nodules, pain, and thrombophlebitis as an adverse reaction to gadolinium contrast media.
    Murphy KJ; Hansen R; Prince MR
    AJR Am J Roentgenol; 1997 Jul; 169(1):318-9. PubMed ID: 9207574
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications.
    Niendorf HP; Alhassan A; Geens VR; Clauss W
    Invest Radiol; 1994 Jun; 29 Suppl 2():S179-82. PubMed ID: 7928222
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of the tolerability of gadodiamide, a new nonionic contrast agent in MRI of the central nervous system].
    Aslanian V; Lemaignen H; Bunouf P; Schiratti M; Lambrechts M; Lundby B; Borseth A; Svaland M
    J Radiol; 1995 Jul; 76(7):431-4. PubMed ID: 7473377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA.
    Balériaux D; Matos C; De Greef D
    Neuroradiology; 1993; 35(7):490-4. PubMed ID: 8232870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.